Samsung Shares Rise on $72 Billion Shareholder Return Plan 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Add as a preferred source on Google
GAITHERSBURG, Md., May 08, 2018 -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2018 before the market open and host a conference call on Wednesday, May 16.
Conference Call Details
Date: Wednesday, May 16
Time: 8:30am Eastern Time
Domestic: 888-394-8218
International: 323-701-0225
Conference ID: 1336227
Webcast: http://public.viavid.com/index.php?id=129546
Replays, Available through May 30th:
Domestic: 844-512-2921
International: 412-317-6671
Replay PIN: 1336227
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
[email protected]
Ashley Robinson
LifeSci Advisors, LLC
617-535-7742
[email protected]
